Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study. The post Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity appeared first on Investor's Business Daily.
Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.
The post Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
